Abstract PR12: Genomic landscape of immunotherapy resistance in lung cancer

Immune checkpoint inhibitors (ICI) have emerged as an important modality in lung cancer treatment. However, studies have shown that only a fraction of patients will experience any clinical benefit when treated with ICI, and a better understanding of the mechanisms of resistance is still needed. In this study, we sought to characterize the prevalence of known mechanisms of primary and adaptive resistance in the context of the greater immunogenomic landscape in a real-world cohort of 100 non-small cell lung cancer patients treated with ICI. Targeted panel DNA sequencing and whole-transcriptome RNA sequencing were performed on a primary tumor biopsy for each patient, the clinical notes were abstracted and structured, and the digital image of the HE 2019 Nov 17-20; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(3 Suppl):Abstract nr PR12.